Invitations to National or International Conferences- Stephen G. Swisher, M.D.

---

1. Gamma Interferon and Tumor Necrosis Factor Reverse Interleukin-4 Suppression of Lymphokine-Activated Killer Induction, American Association for Cancer Research, San Francisco, CA, May, 1989.
2. The Role of Secondary Cytokines in IL-4 Inhibition of Lymphokine-Activated Killer Cell Induction, University of California, Los Angeles, Surgical Oncology Conference, Los Angeles, CA, April, 1989.
3. IL-4 Down-Regulation of IL-2 Induced IFN-Gamma Protein Production Correlates with IL-4 Suppression of LAK Activity, Society for Leukocyte Biology, Marcos Island, FL, October, 1989.
4. Alveolar Macrophages Inhibit Tumor Infiltrating Lymphocyte Cytotoxicity, Society of University Surgeons Residents' Program, Los Angeles, CA, February, 1990.
5. Suppression of Tumor-Infiltrating Lymphocytes by Pulmonary Macrophages, University of California, Los Angeles, Surgical Oncology Conference, Los Angeles, CA, March, 1990.
6. Immunopathologic Features of Human Lung Tumors Following Pre-Operative Interleukin-2 Therapy, American Society of Clinical Oncology, Washington, D.C., May, 1990.
7. Inhibition of Tumor Infiltrating Lymphocytes by Alveolar Macrophages, American Association for Cancer Research, Washington, D.C., May, 1990.
8. Pulmonary Macrophage Inhibition of Interleukin-2 Induction of Tumor Infiltrating Lymphocytes, American Association of Immunology, New Orleans, LA, June, 1990.
9. Pancreatitis Associated with Adult Choledochal Cysts, Society for Surgery of the Alimentary Tract, Boston, MA, May, 1993.
10. Management of Pancreatitis Complicating Pregnancy, Southern California Chapter of the American College of Surgeons, Newport Beach, CA, January, 1994.
11. Biliary Disease During Pregnancy: A Surgical Disorder, Southwestern Surgical Congress, Tucson, AZ, April, 1994.
12. Clinical Gene Therapy, Gene Therapy Conference, University of California, Los Angeles Medical Center, Los Angeles, CA, May, 1994.
13. Perioperative Blood Product Transfusions Decrease Long-Term Survival in Esophageal Cancer, Society of Surgical Oncology, Boston, MA, March, 1995.
14. Blood Transfusions and Decreased Survival in Esophageal Cancer, Texas Heart Institute, Houston, TX, June, 1995.
15. The Role of Neoadjuvant Therapy and Surgical Resection in Esophageal Cancer, Pacific Coast Surgical Association, San Diego, CA, February, 1996.
16. Short and Long-Term Outcomes Following Esophagogastrectomy in Elderly Patients, Society of Surgical Oncology, Chicago, IL, March, 1997.
17. Persistent Transgene Expression Following Repeated Injections of a Recombinant Adenovirus Containing the p53 Wildtype Gene in Patients with Non-Small Cell Lung Cancer, American Association for Cancer Research, San Diego, CA, April, 1997.
18. Adenoviral p53 Treatment in Advanced Non-Small Cell Lung Cancer, Society for Biological Therapy, The Cancer Vaccines Session, Pasadena, CA, October, 1997.
19. Impact of Number of Involved Lymph Nodes on Long-term Survival in Esophageal Cancer, The Society of Surgical Oncology, San Diego, CA, March, 1998.
20. Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer with p53 Gene Transfer, American Lung Association/American Thoracic Society International Conference, Chicago, IL, April, 1998.
21. Multimodality Therapy of Resectable Non-Small Cell Lung Cancer: Role of New Agents, American Lung Association/American Thoracic Society International Conference, Chicago, IL, April, 1998.
22. Adenoviral Mediated p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer, American Society of Clinical Oncology, Los Angeles, CA, May, 1998.
23. ASCO '98 Review: Gene Therapy Trials, American Society of Clinical Oncology, Flint, MI, June, 1998.
24. Surgery in the Multimodality Approach to Esophageal Cancer, Peruvian Medical Oncology Society Conference, Lima, Peru, October, 1998.
25. Gene Therapy of Lung Cancer, Third Annual VA Oncology Conference, San Antonio, TX, October, 1998.
26. Adenoviral p53 Gene Transfer in Non-Small Cell Lung Cancer, ASTRO 40th Annual Meeting, Phoenix, AZ, October, 1998.
27. Thoracic Surgery in Patients with Non-Small Cell Lung Cancer After Neoadjuvant Therapy, 10th Annual Lung Cancer Symposium, Orange, CA, November, 1998.
28. Adenoviral Mediated p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer, 41st Annual Clinical Conference, New Frontiers Research, November, 1998.
29. Multimodality Therapy of Lung Cancer, Chemotherapy Foundation Symposium, Mount Sinai Medical Center, New York, NY, November, 1998.
30. Non-Small Cell Lung Cancer - Resectable Disease, Medical and Clinical Directors Conference, Coronado, CA, December, 1998.
31. Impact of Operative Volume On Morbidity, Mortality and Hospital Usage Following Esophagectomy for Esophageal Cancer, Western Thoracic Surgical Association, Squaw Valley, CA., January, 1999.
32. Gene Therapy for Lung Cancer: Fact or Fiction, Thoracic Malignancies Conference, University of Iowa, Cedar Rapids, IA., March, 1999.
33. Use of Neoadjuvant and Adjuvant Taxol, Japanese Association of Chest Surgeons Luncheon Seminar, Isaka Kansai, Japan, May, 1999.
34. New Aspects of Combined-Modality for Non-Small Cell Lung Cancer, Keynote Speaker for 16th Annual Meeting of Japanese Association of Chest Surgeons, Tokyo, Japan, May, 1999.
35. Multidisciplinary Approach to Resectable Non-Small Cell Lung Cancer, Frontiers of Oncology Annual Conference, North Shore University Hospital, Manhassett, NY, June, 1999.
36. Surgical Treatment of Esophageal Cancer, Oncology 2000 Symposium , Albert Einstein Hospital, Sao Paulo, Brazil, August, 1999.
37. Neo-adjuvant Therapy for Non-Small Cell Lung Cancer, Oncology 2000 Symposium , Albert Einstein Hospital, Sao Paulo, Brazil, August, 1999.
38. Multimodality Treatment of Non-Small Cell Lung Cancer, Hillcrest Baptist Medical Center, Waco, TX, August, 1999.
39. Treatment of Advanced Lung Cancer with Adenoviral p53, Millennium Conference on Nucleic Acids, Clearwater, FL, January, 2000.
40. Intergroup S9900: Surgical and Other Issues, Non-Small Cell Lung Cancer Mult-Modality Speaker Program, Miami Beach, FL, February, 2000.
41. Adenoviral mediated Bak gene transfer induces apoptosis in mesothelioma cell lines, American Association for Thoracic Surgery Annual Meeting, Toronto, Canada, May, 2000.
42. Adp53 Treatment of Non-Small Cell Lung Cancer, Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention, Dublin, Ireland, May, 2000.
43. A Phase II Trial of Adenoviral Mediated p53 Gene Transfer (RPR/INGN 201) in Conjunction with Radiation Therapy in Patients with Localized NSCLC, American Society of Clinical Oncology Annual Meeting, New Orleans, LA, May, 2000.
44. Early Detection and Combined-Modality Treatment of Lung Cancer, The American College of Chest Physicians (ACCP) San Francisco, CA, October, 2000.
45. Treatment Strategies for Resectable Non-small Cell Lung Cancer (NSCLC), First Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, February 2001.
46. New concepts in the biology and treatment of cancer, Japan/US Cancer Therapy Symposium "New Concepts in the Biology and Treatment of Cancer". La Jolla, CA, April 2001.
47. Lung Cancer: Progress, Biology, and Clinical Implications; Immunobiology and Biologic Therapy,. Am. Soc. Clin. Oncol., San Francisco, CA, May 2001.
48. Is Surgical Salvage Indicated for Recurrent Esophageal Tumors following Definitive Chemoradiation? Am. Assoc. Thorac. Surg. San Diego, CA, May 2001.
49. Ad-p53 Gene Therapy Trials in Lung Cancer. 2nd Annual Opinion Leader Summit: Targeted Therapies in the Treatment of Lung Cancer. Scottsdale, AZ, February 2002.
50. Adenoviral MDA-7 induces apoptosis in lung cancer cells through mitochondrial permeability transition. Am. Assoc. Thorac. Surg., Washington, D.C., May 2002.

Back to Top